Welcome to our dedicated page for Reliance Global Group SEC filings (Ticker: EZRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Reliance Global Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Reliance Global Group's regulatory disclosures and financial reporting.
Reliance Global Group formed LifeSci Global Group LLC, a majority-owned healthcare investment vehicle, and funded it using a Promissory Note of up to $2,000,000 from its subsidiary EZRA International Group.
LifeSci Global agreed to purchase up to 421,053 Innervate Radiopharmaceuticals units at $4.75 per unit, totaling about $2.0 million, with $500,000 funded at closing. The deal includes priority distributions and up to 210,526 warrants and was approved by independent directors as a related-party transaction, with committee reshuffling to ensure board independence.
Reliance Global Group, Inc. filed a post-effective prospectus supplement updating its registration to cover the securities issued in its January 29, 2026 public financing and the ongoing issuance of shares upon exercise of related warrants. The January 2026 Offering sold 7,219,259 shares, 188,149 pre-funded warrants, 14,814,816 common warrants and issued 518,519 placement agent warrants at a combined public offering price of $0.27 per unit (or $0.269 per pre-funded unit), generating gross proceeds of approximately $2.0 million. The prospectus registers up to 15,521,484 shares issuable upon exercise of the issued warrants, and summarizes exercise terms (common warrant exercise price $0.27, pre-funded warrant exercise price $0.001, placement agent warrant exercise price $0.3375) and related transfer, beneficial-ownership limitations and cashless-exercise provisions.
The filing also discloses recent corporate developments including the launch of EZRA International/Scale51, a staged equity investment in Enquantum (16% ownership to date, target 51% via milestone tranches), amendments expanding an equity line commitment to $50.0 million, repayment of approximately $5.0 million of long-term debt in 2025, adoption of a digital asset treasury strategy, and corporate governance updates (restated articles and amended bylaws). The company’s Nasdaq ticker changed to EZRA and the last reported sale price on April 28, 2026 was $0.1753 per share.
Reliance Global Group, Inc. (EZRA) updates its Form S-1 by converting the prospectus into a short-form post-effective amendment covering 7,219,259 shares of Common Stock, 188,149 Pre-Funded Warrants, 14,814,816 Common Warrants and 518,519 Placement Agent Warrants (and up to 15,521,484 shares issuable upon exercise).
The amendment reflects the closed January 29, 2026 public financing that generated approximately $2.0 million gross ($1.7 million net after fees), the Nasdaq ticker change to EZRA, launch of EZRA International and the Scale51 model, the Enquantum investment and amendments to the White Lion equity line extending capacity up to $50.0 million.
Reliance Global Group has launched RELI Exchange 2.0, the next phase of its InsurTech platform for independent insurance agencies, aimed at faster and more efficient growth. The company previously reported that health insurance policies written through RELI Exchange during the 2025 open enrollment period increased 72% year over year, while Personal Lines Property and Casualty written premium rose 36% year over year. Its broker network expanded from approximately 65 to about 300 agency partners since 2022. RELI Exchange 2.0 centralizes recruiting with defined pipeline stages, integrated task management and full communication tracking to support higher recruiting volumes without additional headcount and to lay groundwork for future automation and data-driven capabilities.
Reliance Global Group, Inc. Chairman and CEO Ezra Beyman reported an open-market purchase of 300,000 shares of Common Stock at a price of 0.1699 per share. Following this transaction, he directly holds 959,299.997 shares, with additional smaller indirect holdings through YES Americana Group, LLC and Reliance Global Holdings, LLC.
Reliance Global Group, Inc. filed an amendment to its annual report for the year ended December 31, 2025 to correct the list of exhibits. The company had inadvertently omitted its Compensation Recovery Policy dated November 13, 2023, which is now added as Exhibit 97.1.
The amendment also includes current-dated CEO and CFO certifications under Section 302 of the Sarbanes-Oxley Act but makes no changes to the financial statements or other disclosures in the original report. As of March 10, 2026, the company had 21,253,013 common shares outstanding, and non-affiliate common stock held a market value of about $5.3 million as of June 30, 2025.
Reliance Global Group, Inc. Chief Financial Officer Joel Markovits reported an open-market sale of common stock. On March 24, 2026, he sold 127,562 shares of Reliance Global common stock at an average price of $0.2055 per share. Following this transaction, he directly owns 127.59 shares of the company’s common stock.
Reliance Global Group is asking stockholders to approve several key items at its virtual 2026 annual meeting on May 6, 2026. Holders of 21,253,013 common shares as of March 5, 2026 can vote.
Stockholders will vote to elect five directors, ratify Urish Popeck & Co., LLC as auditor for 2026, and amend the 2025 Equity Incentive Plan to raise the share pool from 2,000,000 to 16,000,000 shares. They are also asked to approve, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of common stock under a $50,000,000 equity line of credit with White Lion Capital. This arrangement contemplates up to 11,407,273 shares, described as approximately 54% of shares outstanding as of March 12, 2026, subject to pricing, caps and ownership limits. A separate proposal would allow adjournment of the meeting to solicit additional proxies if needed.
The Board unanimously recommends voting in favor of all proposals and outlines executive and director compensation, governance structure, insider ownership of 6.33% by directors and officers as a group, and late Section 16 filings by certain insiders.